LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Home・Akciju saraksts・Emergent BioSolutions Inc

Emergent BioSolutions Inc

Slēgts

SektorsVeselības aprūpe

12.41 -1.35

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.2

Max

12.56

Galvenie mērījumi
By Trading Economics
Ienākumi	63M 51M
Pārdošana	90M 231M
P/E Sektora vidējais	9.419 78.892
Peļņas marža	22.155
Darbinieki	900
EBITDA	95M 96M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+18.76% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	164M 683M
Iepriekšējā atvēršanas cena	13.76
Iepriekšējā slēgšanas cena	12.41

Ziņu noskaņojums

By Acuity

34%

66%

88 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

4.95 / N/A Atbalsts un pretestība

Emergent BioSolutions Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 24. dec. 21:41 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

2025. g. 26. dec. 20:22 UTC

Tirgus saruna

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

2025. g. 26. dec. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

2025. g. 26. dec. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

2025. g. 26. dec. 17:45 UTC

Tirgus saruna

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

2025. g. 26. dec. 15:52 UTC

Tirgus saruna

Oil Futures Turn Lower After Steady Start -- Market Talk

2025. g. 26. dec. 14:58 UTC

Tirgus saruna

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

2025. g. 26. dec. 14:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

2025. g. 26. dec. 14:28 UTC

Tirgus saruna

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

2025. g. 26. dec. 13:47 UTC

Tirgus saruna

Oil Futures Steady in Thin Holiday Trade -- Market Talk

2025. g. 26. dec. 07:22 UTC

Tirgus saruna

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

2025. g. 26. dec. 05:03 UTC

Tirgus saruna

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 26. dec. 03:38 UTC

Tirgus saruna

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 26. dec. 02:44 UTC

Tirgus saruna

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

2025. g. 26. dec. 01:39 UTC

Tirgus saruna

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

2025. g. 26. dec. 01:14 UTC

Tirgus saruna

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

2025. g. 26. dec. 00:34 UTC

Tirgus saruna

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

2025. g. 26. dec. 00:15 UTC

Tirgus saruna

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

2025. g. 25. dec. 23:42 UTC

Tirgus saruna

Nikkei May Trade in Range; Yen in Focus -- Market Talk

2025. g. 25. dec. 23:40 UTC

Tirgus saruna

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

2025. g. 25. dec. 00:20 UTC

Iegādes, apvienošanās, pārņemšana

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

2025. g. 24. dec. 22:22 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

2025. g. 24. dec. 21:26 UTC

Iegādes, apvienošanās, pārņemšana

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 24. dec. 19:35 UTC

Tirgus saruna

Treasury Yields Decline Ahead of Christmas -- Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Global Equities Roundup: Market Talk

2025. g. 24. dec. 19:09 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

2025. g. 24. dec. 19:06 UTC

Tirgus saruna

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Salīdzinājums

Cenas izmaiņa

Emergent BioSolutions Inc Prognoze

Cenas mērķis

By TipRanks

18.76% augšup

Prognoze 12 mēnešiem

Vidējais 15 USD 18.76%

Augstākais 15 USD

Zemākais 15 USD

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

1 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 1 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Emergent BioSolutions Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

4.95 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Noskaņojums

By Acuity

88 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Emergent BioSolutions Inc

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.